An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 910 participants.

Also called NCT01281306

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 910 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01281306
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Canada, Hungary, India, Romania, Slovakia, South Korea, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01281306. Randomized; double masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2011-12 (actual). Results posted on 2015-08-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension
Condition
Systolic Hypertension
Intervention (Drug)
LCZ696
Intervention (Drug)
Valsartan
Intervention (Drug)
AHU377
Intervention (Drug)
Placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01281306
Content hash
46e08afe592accd5d93a38fd3dbea857fb2eceb54ff07399b4c1f46670bad2fc